Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection

Data is limited on the immunogenicity of the COVID-19 two-vaccination series among patients with hematologic malignancies and current guidelines do not recommend routine monitoring for post-vaccine antibodies. However, we describe three patients who developed severe or critical COVID-19 infections s...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasikhova, Yanina, Morrison, Austin R., Katzman, Ju Hee, Syed, Misbahuddin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744183/
https://www.ncbi.nlm.nih.gov/pubmed/35001670
http://dx.doi.org/10.1177/10732748211070720
_version_ 1784630064874258432
author Pasikhova, Yanina
Morrison, Austin R.
Katzman, Ju Hee
Syed, Misbahuddin
author_facet Pasikhova, Yanina
Morrison, Austin R.
Katzman, Ju Hee
Syed, Misbahuddin
author_sort Pasikhova, Yanina
collection PubMed
description Data is limited on the immunogenicity of the COVID-19 two-vaccination series among patients with hematologic malignancies and current guidelines do not recommend routine monitoring for post-vaccine antibodies. However, we describe three patients who developed severe or critical COVID-19 infections six months after vaccination. This highlights the importance of routine testing of COVID-19 IgG Spike, semi-quantitative antibodies post-vaccination, particularly among immunocompromised patients.
format Online
Article
Text
id pubmed-8744183
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-87441832022-01-11 Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection Pasikhova, Yanina Morrison, Austin R. Katzman, Ju Hee Syed, Misbahuddin Cancer Control Brief Report Data is limited on the immunogenicity of the COVID-19 two-vaccination series among patients with hematologic malignancies and current guidelines do not recommend routine monitoring for post-vaccine antibodies. However, we describe three patients who developed severe or critical COVID-19 infections six months after vaccination. This highlights the importance of routine testing of COVID-19 IgG Spike, semi-quantitative antibodies post-vaccination, particularly among immunocompromised patients. SAGE Publications 2022-01-08 /pmc/articles/PMC8744183/ /pubmed/35001670 http://dx.doi.org/10.1177/10732748211070720 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Brief Report
Pasikhova, Yanina
Morrison, Austin R.
Katzman, Ju Hee
Syed, Misbahuddin
Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection
title Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection
title_full Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection
title_fullStr Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection
title_full_unstemmed Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection
title_short Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection
title_sort immunogenicity of the covid-19 two-vaccination series among hematologic malignancies: report of three cases of breakthrough infection
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744183/
https://www.ncbi.nlm.nih.gov/pubmed/35001670
http://dx.doi.org/10.1177/10732748211070720
work_keys_str_mv AT pasikhovayanina immunogenicityofthecovid19twovaccinationseriesamonghematologicmalignanciesreportofthreecasesofbreakthroughinfection
AT morrisonaustinr immunogenicityofthecovid19twovaccinationseriesamonghematologicmalignanciesreportofthreecasesofbreakthroughinfection
AT katzmanjuhee immunogenicityofthecovid19twovaccinationseriesamonghematologicmalignanciesreportofthreecasesofbreakthroughinfection
AT syedmisbahuddin immunogenicityofthecovid19twovaccinationseriesamonghematologicmalignanciesreportofthreecasesofbreakthroughinfection

Ejemplares similares